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ABSTRACT
Tumourigenic transformation of normal cells into
cancer typically involves several steps resulting in
acquisition of unlimited growth potential, evasion
of apoptosis and non-responsiveness to growth
inhibitory signals. Both genetic and epigenetic
changes can contribute to cancer development
and progression. Given the vast genetic heterogen-
eity of human cancers and difficulty to monitor
cancer-initiating events in vivo, the precise relation-
ship between acquisition of genetic mutations and
the temporal progression of epigenetic alterations
in transformed cells is largely unclear. Here, we
use an in vitro model system to investigate the con-
tribution of cellular immortality and oncogenic
transformation of primary human cells to epigenetic
reprogramming of DNA methylation and gene ex-
pression. Our data demonstrate that extension of
replicative life span of the cells is sufficient to
induce accumulation of DNA methylation at gene
promoters and large-scale changes in gene expres-
sion in a time-dependent manner. In contrast,
continuous expression of cooperating oncogenes
in immortalized cells, although essential for anchor-
age-independent growth and evasion of apoptosis,
does not affect de novo DNA methylation at pro-
moters and induces subtle expression changes.
Taken together, these observations imply that
cellular immortality promotes epigenetic adaptation
to highly proliferative state, whereas transforming
oncogenes confer additional properties to trans-
formed human cells.
INTRODUCTION
It is widely recognized that tumours and tumour-derived
cell lines exhibit altered patterns of DNA methylation and
gene expression in comparison with normal tissues and
primary cells. Gain of DNA methylation at normally
DNA methylation-free gene promoters and extensive
loss of DNA methylation throughout the genome have
been detected in a variety of tumour types (1–4).
Aberrant methylation of gene promoters can lead to
stable silencing of tumour suppressor genes and consti-
tutes an alternative mechanism to genetic loss of gene
function that can be brought about by mutations, dele-
tions and chromosomal rearrangements (1,3,4). Loss of
DNA methylation from repetitive sequences is thought
to promote genomic instability, which often accompanies
cancer progression (5,6).
Despite the wealth of data documenting these ﬁndings,
it is largely unclear when and how the changes in DNA
methylation occur in transformed human cells (3).
Tumours usually initiate from a small number of mutant
cells, and these tumour-initiating cells are difﬁcult to
detect, isolate and monitor in long-term studies (7).
Similar limitations apply to most available mouse cancer
models. The vast majority of epigenetic studies on human
cancers are carried out either on limited amount of clinical
material isolated from patients when the disease is well
advanced or on cell lines established from tumours and
maintained in culture for extended periods of time.
Although data indicating strong correlation between
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accumulated epimutations and tumour grade/type are
available for colon, lung, prostate and breast cancer
(8–11), the precise timing of the initial methylation
events and the progression of epigenetic alterations in
human cells undergoing tumourogenic transformation
have been difﬁcult to estimate due to the vast genetic het-
erogeneity of human cancers. In most cases, it is extremely
challenging to determine the precise relationship between
genetic background, oncogenic mutations, genomic
instability and detected epigenetic changes (12).
To circumvent these limitations and generate a cancer
model system amenable to long-term tracking of epigenetic
events and further mechanistic studies, we used an estab-
lished method to transform human somatic cells in vitro
using a combination of well-deﬁned factors (13). We estab-
lished isogenic immortalized and transformed human cell
lines derived from primary foetal lung ﬁbroblasts (MRC-5)
and followed the temporal changes in gene expression and
DNAmethylation at gene promoters in these independent,
but related to each other, cell populations. Our analyses
show that MRC-5 cells, immortalized by expression
of human telomerase reverse transcriptase (hTERT)
catalytic subunit, and transformed MRC-5 cells, express-
ing hTERT, SV40 large T-antigen (T-Ag) and constitu-
tively active oncogenic H-RASGV12, progressively
accumulate extensive changes in gene expression and
de novo DNA methylation at gene promoters that
become apparent after 50 population doublings (pd) in
culture. Remarkably, de novo DNA methylation at gene
promoters occurred at speciﬁc loci with similar timing
in both the immortalized and transformed cell lines sug-
gesting that gain of DNA methylation does not require
expression of oncogenes. The accumulation of DNA
methylation at gene promoters took place predominantly
at genes that were transcriptionally inactive in the parental
cell line, but did not correlate with pre-existing Polycomb-
dependent H3K27 trimethylation (H3K27me3) previously
reported to pre-mark promoters for de novo DNA methy-
lation (14–16). Importantly, immortalized and trans-
formed cell lines displayed different gene expression
proﬁles, indicating that the presence of oncogenes modu-
lates the properties of immortal cells. Our data demon-
strate that programmed de novo DNA methylation at
speciﬁc loci and adaptation of transcriptional output of
the genome to a highly proliferative state can occur in
diploid human cells without a major input from oncogenic
proteins. On the other hand, transforming oncogenes con-
tribute to further modulation of gene expression and
promote evasion of apoptosis and anchorage-independent
growth, which are essential properties of cancer cells.
MATERIALS AND METHODS
Cell lines and viral infections
The human male foetal lung ﬁbroblast cell line MRC-5
(ATCC number: CRL-171) and all MRC-5-derived
cells were cultured in MEM (Life Sciences) supplemented
with 10% foetal calf serum, 1mM non-essential amino
acids, 1mM sodium pyruvate, 100U/ml penicillin,
1mg/ml of a streptomycin and 2mM L-glutamine. The
pBABE-Neo-hTERT, pBABE-Hygro-SV40 T-Ag and
pBABE-Puro-H-RASV12G plasmids were packaged into
retroviral particles in amphotropic Phoenix A cell line.
Culture supernatants were harvested 48 h later and the
retroviral titres determined by infection of NIH-3T3
mouse ﬁbroblast cells. The MRC-5hTERT cell line was
generated by infecting 105 MRC-5 cells with pBABE-
Neo-hTERT retroviral particles at multiplicity of
infection (MOI)=1 in the presence of 4 mg/ml polybrene.
After a 7-day selection with 250 mg/ml G418, drug-resist-
ant colonies were pooled and designated as passage 1. The
MRC-5TSR cell line was generated by infecting the MRC-
5hTERT with retroviral particles carrying pBABE-Hygro-
T-Ag and subsequently after selection with 150mg/ml
hygromycin for 7 days with packaged pBABE-Puro-H-
RASV12G. Selection with 1 mg/ml puromycin was
applied and resistant cells were pooled and designated as
passage 1.
Growth curves
A total of 5104 cells were initially seeded (cell input= n0)
into six-well dishes, and the cell yields (n) were recorded
at each passage and the population doublings calculated
from the formula MPD (mean population doubling)=
3.32 (log10 n- log10 n0).
Soft agar assays
A bottom layer of 10ml 1.6% agar (BioGene) in MRC-5
growth medium was prepared in 10-cm tissue culture
dishes and allowed to solidify. Each cell line (set up in
triplicate) was seeded at a density of 105 cells/dish in a
4ml top layer of 0.8% agar in MRC-5 growth medium.
Cells were incubated at 37C with weekly overlays with
4ml of top layer agar without cells. After 6–8 weeks
colonies were scored blind.
Telomere repeat ampliﬁcation protocol
Cell extracts were prepared and assayed for telomerase
activity using the TRAPeze kit (Millipore), following the
manufacturer’s instructions. Pilot experiments were ini-
tially carried out on a range of protein concentrations
(0.2–2 mg) to determine the linear range for each cell line.
Assays were routinely carried out using 1 mg of protein
extract for each cell line. The polymerase chain reaction
(PCR) products were resolved on 10% non-denaturing
polyacrylamide gel, visualized by staining with SYBR
Green and scanned at 473 nm on FLA-5100 scanner.
Telomere restriction fragment Southern blots
Five microgram of genomic DNA prepared from each of
the cell lines was digested with Hinf I and Rsa I restriction
enzymes overnight at 37C. The digests were resolved in a
1% Tris–Acetate–EDTA gel and transferred to Zeta-
Probe GT membrane (BioRad) with 0.4M NaOH for
16 h. The DNA was cross-linked to the membrane using
a ultraviolet cross-linker (Stratagene) set on autocross-link
mode (120 000 mJoules) and the blot hybridized with a
radiolabelled oligonucleotide probe [(TTAGGG)3] at
42C overnight in buffer containing 1mM ethylenediami-
netetraacetic acid (EDTA), 0.5M NaHPO4 and 7%
sodium dodecyl sulphate (SDS). The blot was
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subsequently washed with 3 saline-sodium citrate (SSC),
0.1% SDS at 42C and exposed to X-ray ﬁlm at 70C.
Western blots
Total cell extracts were prepared from 1107 cells by
resuspending the cell pellet in 2ml of lysis buffer (10mM
Tris–HCl pH 7.5, 1mM MgCl2, 1mM EGTA, 5mM b-
mercaptoethanol, 0.5% Cholamidopropyl- dimethylam-
moniopropanesulfonate (CHAPS) (Sigma C-5849) and
10% glycerol) and incubated on ice for 30min. The cells
were centrifuged at 13 000 rpm for 30min at 4C and
supernatants taken. Nuclear extracts were prepared as
previously described (17). Fifty microgram of either total
cell protein extract or nuclear extract prepared from
indicated cell lines was resolved on either 10 or 15%
sodium dodecyl sulphate–polyacrylamide gel electrophor-
esis gels and transferred to polyvinylidene ﬂuoride
(PVDF) membrane (Biorad). The blots were probed
with anti-SV40 T-antigen (Santa Cruz sc-148), anti- H-
RAS (Santa Cruz sc-520), anti HDAC-1 (Santa Cruz sc-
7872) and anti-tubulin (Cancer Research UK) antibodies
in 1Tris-buffered saline (TBS) buffer with 0.1% Tween
20 followed by appropriate secondary anti-mouse IR800
and anti-rabbit IR670 antibodies (LiCOR Biosciences).
Images were collected on Odyssey scanner (LiCOR
Biosciences) and quantiﬁed with Image Studio software
(LiCOR Biosciences).
Immunohistochemistry
A total of 2 105 cells were seeded onto 19-mm coverslips
in six-well dishes and 0.6mM H202 added for 2 h. Cells
were then washed with phosphate-buffered saline (PBS)
and allowed to recover overnight in growth media. After
ﬁxation in 3% formaldehyde for 15min, the cells were
incubated in blocking solution (PBS with 5% bovine
serum albumin and 0.3% Triton X-100) for 1 h and then
incubated with anti-p21 antibody (Cell Signalling # 2947)
overnight at 4C. The cells were rinsed three times with
PBS and incubated for 2 h with Alexa 488 conjugated sec-
ondary antibody. Finally, the cells were washed with PBS,
counter stained with diamidino-2-phenylidole (DAPI) and
mounted in Prolong Gold (Life Sciences). Images were
taken at 20 magniﬁcation on Olympus BX61 ﬂuores-
cence microscope equipped with ColorViewII camera
and AnalySIS software.
Methylated DNA afﬁnity puriﬁcation
Afﬁnity puriﬁcation of methylated DNA (MAP) was
carried out essentially as described (18). Brieﬂy, genomic
DNA from MRC-5 cells, MRC-5hTERT (50 and 100 pd)
and MRC-5TSR (50 and 100 pd) was digested with MseI,
and 50 mg of digested DNA was loaded onto 1ml chroma-
tography column (Tricorn, GE Healthcare) containing
50mg of His-tagged methyl-CpG binding domain of
MeCP2 protein bound to nickel-charged Chelating
Sepharose Fast Flow (GE Healthcare). The column was
washed with 10 volumes of buffer A [20mM HEPES pH
7.5, 100mM NaCl, 0.1% Tween 20, 10% glycerol, 0.5mM
phenylmethylsulfonyl ﬂuoride (PMSF)] followed by
buffer A with increasing concentration of NaCl
(0.1–0.7M). Methylated DNA was eluded with buffer A
containing 1M NaCl. Triplicate runs were done for each
of the cell lines and methylated fractions identiﬁed by
PCR for known methylated regions. The methylated
fractions were pooled, concentrated and subjected to
whole-genome ampliﬁcation (WGA kit, Sigma Aldrich)
alongside MseI-digested input genomic DNA. Ampliﬁed
samples were labelled with Cy3 and Cy5, respectively, and
co-hybridized to H18-RefSeq promoter microarrays
(Roche NimbleGen). The data from promoter microarray
experiments can be assessed at ArrayExpress, accession
number E-MTAB-2005.
Promoter microarray data analyses
The normalization of the microarray data and analyses of
promoter regions were carried out with custom-designed
software ‘Prometheus’ essentially as described previously
(17). Brieﬂy, raw ﬂuorescent intensity values were Loess
normalized using LIMMA package in R, and the log2
values for either MAP/input or ChIP/input were
calculated for each individual probe. Subsequently, for
comparison between microarray experiments, the probe
values were scaled to have the same median absolute
deviation. The log2 values of all probes located within a
1000-bp window around the transcription start site (TSS)
(+500 to 500) were aggregated into a single median log2
value for each promoter.
Chromatin immunoprecipitation
Chromatin immunoprecipitations (ChIPs) were carried out
in triplicate as described (19) with antibodies against
acetylated H3 (Millipore, 06–599) and H3K27me3
(Millipore, 07–449). ChIP and input DNA were ampliﬁed
using WGA kit (Sigma), labelled with Cy-dyes and
hybridized to H18-RefSeq promoter microarrays (Roche
NimbleGen). Microarray data were analysed as described
above. The data from ChIP experiments can be assessed at
ArrayExpress, accession number E-MTAB-2004.
Sodium bisulphite DNA sequencing
Sodium bisulphite treatment was carried out essentially as
described (20) and processed for sequencing as outlined in
(21). PCR primers were designed manually or using
MethPrimer software (22) and are available on request.
The PCR products were cloned using the CloneJet PCR
Cloning Kit (Thermo Scientiﬁc) and sequenced using
BigDye Terminator v3.1 reagents (Applied Biosystems).
BiQ Analyzer software (23) was used to analyse the
methylation status of sequences.
Methylated DNA immunoprecipitation
Methylated DNA immunoprecipitation (MeDIP) was
performed as described (24) with minor modiﬁcations.
Genomic DNA was fragmented by sonication to 300–
1000 bp. For each immunoprecipitation, 4 mg of denatured
sonicated DNA was incubated for 2 h at 4C with 10 ml
of anti-5-methylcytosine monoclonal antibody
(Eurogenetec). A total of 40 ml of M280 Dynabeads
conjugated with sheep anti-mouse IgG (Dynal Biotech)
were added and incubated for a further 2 h before
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washing with IP buffer (10mM Na2HPO4pH 7.0; 140mM
NaCl; 0.05% Triton X-100). Proteinase K digestion was
carried out at 50C overnight and the methylated DNA
was recovered using Pure-Link PCR Puriﬁcation Kit
(Life Sciences).
Quantitative PCR
Quantitative PCR was carried out with SYBR Green
Master Mix (Roche) according to manufacturer’s instruc-
tions on a LightCycler 480 (Roche). Quantitative PCR on
MeDIP samples was carried out using 2 ml of MeDIP
DNA and 20 ng of total input DNA. Enrichments in the
MeDIP fraction were calculated as a percentage of input.
Quantitative reverse transcription PCRs were carried
in triplicate using independent complementary DNA
(cDNA) synthesis reactions (Superscript II; Life
Sciences) as template. Three independent RNAs prepar-
ations from three different ﬂasks of cells were used for
cDNA synthesis. Fold changes relative to
Glyceraldehyde-3-phosphate dehydrogenease (GAPDH)
were calculated using the Pfafﬂ method (25). Primer se-
quences are available on request.
Gene expression analyses
Total RNA was puriﬁed using Trizol reagent (Life
Sciences), and double-stranded cDNA was synthesized
from 10 mg of total RNA using SuperScript double-
stranded cDNA synthesis kit (Life Sciences) according
to manufacturer’s instructions. All samples were labelled
with Cy3 dye and hybridized in triplicate to Human Gene
Expression H18 Build 475K expression microarrays
(Roche NimbleGen). Raw intensity values were quantile
normalized using the BioConductor package LIMMA.
The log2 values of the probes associated with each tran-
script were summarized into a single log2 value using
median polish procedure. A linear model was ﬁt to the
data with LIMMA, calculating the expression ratio
M=log2 and moderated t-statistics, adjusting P-values
for multiple testing. The false discovery rate was
obtained using the Benjamini–Hochberg method and
false discovery rate <0.05 cut-off applied to all M
values. The raw data from expression microarray experi-
ments can be downloaded from ArrayExpress, accession
number E-MTAB-2003. Functional gene annotation was
performed by DAVID (http://david.abcc.ncifcrf.gov) (26).
Analyses of IMR90 histone modiﬁcations data
Histone modiﬁcation data for IMR90 cell line correspond-
ing to the set of methylated promoters in MRC-5hTERT
cells at 100 pd were extracted from Ensembl API (version
67) using HMoTF package of script written in Perl, which
retrieved ChIP-seq data from annotated peaks taking into
account the genomic coordinates of the analysed regions.
The data were converted to Z-scores and plotted as heat
maps using the open source TIGR MultiExperiment
Viewer (MeV) software.
RESULTS
Generation of immortalized and transformed cell lines
To follow the epigenetic changes that accompany the
immortalization and transformation of normal diploid
human somatic cells, we generated two isogenic cell lines
with deﬁned characteristics (Figure 1A). First, we
introduced by retroviral infection the catalytic component
of human telomerase (hTERT) into foetal lung ﬁbroblast
cell line MRC-5, which normally has a limited life span in
culture and enters senescence after 20–25 pd.
This step ensured that the immortalized cells stably
maintain their telomeres and do not become aneuploid
after prolonged culturing (Supplementary Figure S1A
and B). After selection for cells expressing hTERT, we
sequentially introduced by retroviral infection into a
subset of hTERT-expressing cells two oncogenes: the
Simian Virus 40 large T-Ag and constitutively active onco-
genic H-RASG12V (Figure 1A). We will refer to these
two cell lines as MRC-5hTERT and MRC-5TSR,
respectively.
Stable expression of hTERT in MRC-5hTERT cells was
sufﬁcient to bypass senescence and extend the proliferative
life span of the parental MRC-5 cell line beyond one year
in culture (Figure 1B). Therefore, the MRC-5hTERT cells
can be designated as immortalized, as has been previously
reported (13,27). To conﬁrm that the extended life span in
culture of MRC-5hTERT cells was due to persistent tel-
omerase activity, we performed a Telomere repeat
ampliﬁcation protocol (TRAP) assays on cell extracts
from early (50 pd; 3 months in culture) and late (100 pd;
6 months in culture) passage cells. In parallel, we also
examined the MRC-5TSR cells to ask whether telomerase
activity is stably maintained in the presence of oncogenes.
We detected a characteristic 6-bp laddering in MRC-
5hTERT and MRC-5TSR cells at 50 and 100 pd, but not in
the parental cell line, and this activity was lost upon heat
inactivation of the extracts (Figure 1C). The absence of
telomerase activity in MRC-5 cell line is consistent with
the limited life span of these cells in culture (Figure 1B).
The level of telomerase activity detected in MRC-5hTERT
and MRC-5TSR cells was sufﬁcient to extend the average
length of telomeres from 6 to> 10 kb as indicated by the
progressive increase in telomere restriction fragment
length (Supplementary Figure S1C).
To conﬁrm that the introduced oncogenes are expressed
continuously in MRC-5TSR cells, we performed western
blots on extracts from the parental cell line as well as
MRC-5hTERT and MRC-5TSR cells at 50 and 100 pd.
These experiments detected robust expression of SV40
T-Ag and elevated levels of H-RAS in the MRC-5TSR
cell line (Figure 1D and E). Because the H-RAS
antibody cannot discriminate between the endogenous
and the mutant RAS protein, we also cloned and
sequenced cDNA from MRC-5TSR cells. This conﬁrmed
the presence of mutant H-RASG12V in MRC-5TSR cell line
and detected a 1:14 ratio of wild-type to mutant H-RAS
messenger RNA (mRNA) (Supplementary Figure S1D).
Taken together, these experiments demonstrate that
hTERT and the introduced oncogenes, SV40 T-Ag and
H-RASG12V, are stably expressed in the transduced
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MRC-5 cells and that this expression does not change
signiﬁcantly over long periods of time in culture.
Characterization of immortalized and transformed
cell lines
The SV40 large T-Ag is known to bind both p53 and pRB
tumour suppressor proteins and impair their normal
function in controlling cell cycle checkpoints upon
cellular stress and cell cycle progression, respectively
(28). To determine whether MRC-5TSR cells display
reduced p53 and Rb activity and thus can be considered
transformed, we investigated their response to oxidative
DNA damage and acquisition of anchorage-independent
growth. Upon treatment with hydrogen peroxide (H2O2),
we observed accumulation of p53-regulated Cyclin-
dependent kinase (CDK) inhibitor protein p21 in the
nuclei of MRC-5 and MRC-5hTERT cells, which lack
SV40 T-Ag and are expected to have normal p53-depend-
ent response (Figure 2A and B; left and middle panels). In
contrast, MRC-5TSR cells expressing SV40 T-Ag did not
accumulate nuclear p21 in response to peroxide treatment
(Figure 2A and B; right panel), indicating that p53-de-
pendent response to DNA damage is abrogated in these
cells.
To examine the acquisition of anchorage-independent
growth by the transformed MRC-5 cells, which should
be largely dependent on constitutive expression of onco-
genic H-RAS (13,29), we scored the ability of MRC-5,
MRC-5hTERT, MRC-5TSR cells and a control squamous
lung carcinoma NCI H-520 cell line to form colonies
in soft agar. Consistent with the stable expression of
H-RASG12V, MRC-5TSR cells grown for either 50 or
100 pd produced robust colonies in soft agar although
with lower frequency than the control H-520 cells
(Figure 2C and D). Neither the MRC-5 cells nor the
immortalized MRC-5hTERT cell line formed colonies in
soft agar (Figure 2C and D). From these experiments,
we conclude that MRC-5hTERT cells, although immortal,
do not have the characteristic transformed properties of
MRC-5TSR cells.
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Figure 1. Generation of immortal and transformed human cell lines. (A) Immortalized (MRC-5hTERT) and transformed (MRC-5TSR) human cell
lines were generated from embryonic lung ﬁbroblasts MRC-5 by stepwise infection with retroviral particles driving the expression of hTERT, SV40
T-Ag and H-RASV12G. ‘Neo’, ‘Hygro’ and ‘Puro’ indicate drug resistance markers neomycin, hygromycin and puromycin, respectively, carried by the
retroviral vectors. (B) Growth of MRC-5, MRC-5hTERT and MRC-5TSR cell lines measured as population doublings over 400 days in culture. The
parental MRC-5 cell line enters senescence after 20 pd. (C) Telomerase activity detected by TRAP in cell extracts from MRC-5, MRC-5hTERT and
MRC-5TSR cells. ‘Ctrl’ is a control telomerase-positive NCI-H520 lung cancer cell line. The ‘plus’ and ‘minus’ symbols indicate whether the extracts
have been subjected to heat inactivation (HI). ‘pd’ represents population doublings. (D) A Western blot probed with anti-SV40 T-Ag antibodies
shows stable expressed of T-Ag only in MRC-5TSR cell. HDAC1 is a loading control. (E) MRC-5TSR cells show elevated levels of H-RAS protein due
to expression of exogenous H-RASV12G (see also Supplementary Figure S1D). a-Tubulin is a loading control.
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Progressive accumulation of DNA methylation
at gene promoters in immortalized and transformed
cell lines
We next asked whether DNA methylation patterns remain
stable in MRC-5hTERT and MRC-5TSR cells over time and
whether the transformation by oncogenes is required to
induce changes in DNA methylation at gene promoters
that are characteristic of many human tumours. To
do so, we used methyl-CpG binding domain afﬁnity puri-
ﬁcation (MAP) of methylated DNA combined with
hybridization to microarrays containing probes for
24 659 human protein-coding RefSeq gene promoters
(Figure 3A). To distinguish signiﬁcant changes in DNA
methylation close to TSS from more distal DNA methyla-
tion patterns, we analysed the microarray data separately
for 1-kb promoter regions (±500 bp from TSS) and the
upstream regions (500 to 1500 bp from TSS), as
described previously (17). A minimal cut-off for median
log2 MAP/input difference between cell lines of 1 (corres-
ponding to 2-fold change in DNAmethylation) was used in
all analyses. We examined DNA methylation at gene pro-
moters in MRC-5hTERT and MRC-5TSR cells at 50 and
100 pd in culture and compared these values with those
for the parental MRC-5 cell line (Figure 3B and
Supplementary Table S1). These analyses detected a pro-
gressive gain of DNA methylation at gene promoters in
immortalized and transformed cells at 50 and 100 pd
compared with the parental cell line. However, we
detected no signiﬁcant differences between MRC-5hTERT
and MRC-5TSR at either 50 or 100 pd when DNA methy-
lation patterns in these cell lines were compared with each
other (Figure 3C). Most de novo DNA methylation events
(250 promoters) occurred late, between 50 and 100 pd,
rather than early (32–70 promoters) (Figure 3B and D)
and affected promoters with low, intermediate and high
CpG density (Figure 4A). Importantly, promoters
methylated early (by 50 pd) remained methylated at late
passages (100 pd) suggesting that once DNA methylation
was established at gene promoters it was stably maintained
through subsequent cell divisions (Figure 3D). De novo
DNA methylation events did not affect preferentially
genes located close to telomeres but occurred at loci
distributed throughout the genome (Supplementary
Figure S2). This suggests that gain of DNA methylation
at gene promoters in MRC-5hTERT and MRC-5TSR cells
did not result from spreading of subtelomeric heterochro-
matin from the extended telomeres.
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Figure 2. Transformation-induced properties of MRC-5TSR cells (A) Immunostaining of MRC-5, MRC-5hTERT and MRC-5TSR cells with antibodies
against SV40 T-Ag (red). The cells were counterstained with DAPI (blue). (B) Immunostaining of H2O2-treated MRC-5, MRC-5
hTERT and MRC-
5TSR cells with anti-p21 antibodies (green) and DAPI (blue). MRC-5TSR cells do not show high levels of p21 induction upon oxidative stress. The
scale bars in (A) and (B) represent 200mm. (C) Micrographs of cells grown in soft agar for 4 weeks. Only the MRC-5TSR cells and the control cell
line NCI-H520 form colonies in soft agar. (D) A table showing the number of colonies formed by MRC-5, MRC-5hTERT, MRC-5TSR and NCI-H520
cells in soft agar. The MRC-5TSR cell line was scored at 50 and 100 pd.
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We further conﬁrmed the presence and timing of DNA
methylation at gene promoters by MeDIP (24), followed
by quantitative PCR at speciﬁc early (SHOX2 and
C1QTNF) and late (BOLA-1) methylated promoters
(Figure 4B), as well as by bisulphite DNA sequencing of
three selected promoters (SHOX2, RPL37 and BOLA-1)
in the parental cell line as well as in the MRC-5hTERT and
MRC-5TSR cells at 50 and 100 pd (Figure 4C). In all cases,
the MeDIP assays and bisulphite DNA sequencing were in
agreement with the microarray data.
Taken together, these analyses indicate that identical
time-dependent changes in DNA methylation at gene
promoters occur in two independent cell populations
and that gain of DNA methylation at promoters does
not require the presence of oncogenes, such as SV40 T-
Ag and oncogenic H-RAS.
De novo DNA methylation occurs predominantly at
inactive gene promoters
It has been reported that promoters that carry chromatin
marked by Polycomb Repressive Complex 2 (PRC2)-de-
pendent repressive histone H3 lysine 27 trimethylation
(H3K27me3) are more susceptible to de novo DNA
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Figure 3. Accumulation of DNA methylation at gene promoters in the immortalized and transformed cell lines. (A) Detection of methylated gene
promoters in MRC-5 cells, early (50 pd) and late (100 pd) passage MRC-5hTERT and MRC-5TSR cell lines by Methylated DNA Afﬁnity Puriﬁcation
(MAP) coupled with hybridization to promoter microarrays representing 24 659 human RefSeq genes. Regions spanning probes from 500 bp to
+500 bp relative to TSS were interrogated. (B) Log2 plots show differentially methylated gene promoters in early and late passage MRC-5
hTERT and
MRC-5TSR cells relative to the parental cell line. Promoters displaying 2-fold gain of DNA methylation are marked in red. Promoters with 2-fold
loss of DNA methylation are marked in blue. (C) Log2 plots comparing DNA methylation patterns at gene promoters between MRC-5
hTERT and
MRC-5TSR cell lines at early (50 pd) and late (100 pd) passages. (D). A heat map visualization of de novo methylated gene promoters (n=301) in
MRC-5hTERT and MRC-5TSR cell lines at early (50 pd) and late (100 pd) passages in comparison with the parental cell line MRC-5. Promoters
methylated at early passage in MRC-5hTERT and MRC-5TSR cells remain methylated in late passage cells.
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methylation during differentiation of embryonic stem cells
to neurons than active promoters marked by H3K4me3
(30). A further correlation between H3K27me3 at gene
promoters in non-transformed cells and gain of DNA
methylation at such sites in lung, colorectal and breast
cancer cell lines has been observed in several independent
studies (14–16). This led to the suggestion that in tumours
there is a frequent switch from the potentially reversible
Polycomb-mediated gene silencing to a more stable long-
term repression by DNA methylation (15).
To examine whether de novo DNA methylation in
MRC-5hTERT and MRC-5TSR cells occurs preferentially
at promoters that are either pre-marked by H3K27me3
or at those associated with actively transcribed genes, we
analysed H3K27me3 and H3 acetylation at gene pro-
moters in the parental MRC-5 cells by ChIP combined
with hybridization to promoter microarrays, as described
earlier in the text. These experiments showed that 28% of
all promoters that acquire DNA methylation in MRC-
5hTERT and MRC-5TSR cells carry H3K27me3 in MRC-5
cells and only 14% are enriched in H3 acetylated chroma-
tin (Figure 5). Both active promoters, enriched in
acetylated H3, and Polycomb-silenced loci, enriched in
H3K27me3 (with few exceptions), displayed a tendency
to be methylated late, by 100, but not by 50 pd, suggesting
that both modiﬁcations delay the appearance of DNA
methylation. However, 58% of promoters that become
de novo methylated in MRC-5hTERT and MRC-5TSR cells
had neither H3K27me3 nor acetylated H3 in the parental
cell line.
Multiple histone modiﬁcations have been mapped by
high-throughput approaches in IMR90 ﬁbroblast cell
line, which similar to MRC-5, is derived from human
foetal lung. Comparison between the two cell lines
revealed broadly similar patterns of H3K27me3 and
histone acetylation at gene promoters as well as presence
of H3K4me3 at loci carrying acetylated H3 (Figure 5).
Given the similarity of chromatin modiﬁcation between
IMR90 and MRC-5 cells, we sought to determine
whether other histone modiﬁcations present at loci that
lack either H3K27me3 or H3 acetylation in MRC-5 cells
could potentiate gain of DNA methylation at gene pro-
moters in MRC-5hTERT and MRC-5TSR cells. Of all the
22 histone modiﬁcations examined in the IMR90 cells,
only H3K36me3, normally present within transcribed
regions of the genome (31–33), was apparent at 19% of
gene promoters that acquire DNA methylation in MRC-
5hTERT andMRC-5TSR cells (Figure 5). Interestingly, many
of the H3K36me3-marked promoters represent alternative
downstream TSSs, which drive the expression of truncated
variant transcripts (Supplementary Figure S3).
Importantly, about half of the loci that were methylated
early (by 50 pd) in the MRC-5hTERT and MRC-5TSR cells
showed enrichment for H3K36me3 in the primary parental
cell line (Figure 5). Taken together, these analyses indicate
that promoters of silenced genes that are either devoid of
known modiﬁcations or enriched for H3K36me3, a modi-
ﬁcation refractive to initiation of transcription (31), are
prone to DNA methylation early in immortalized human
cells, whereas promoters of either actively transcribed or
Polycomb-silenced genes tend to be methylated late, by
100 pd. However, none of the examined chromatin modiﬁ-
cations can be considered predictive of whether or not a
gene promoter will become de novo methylated in
immortalized cells. Many loci carrying similar histone
marks did not accumulate DNA methylation in MRC-
5hTERT and MRC-5TSR cells at late passage in culture.
Immortalized and transformed cells progressively
accumulate changes in gene expression
Given that in MRC-5hTERT cells, we observed gain of
DNA methylation primarily at promoters of genes that
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Figure 5. Histone modiﬁcations at gene promoters that undergo de
novo DNA methylation in the immortalized cells. A heat map repre-
sentation of post-translational histone modiﬁcations (PTMs) found in
the parental MRC-5 cell line and a related foetal lung ﬁbroblast cell
line IMR90 at gene promoters that become methylated in MRC-5hTERT
and MRC-5TSR cell lines. Antibodies against histone H3 acetylated at
K9 and K14 or trimethylated at K27 were used for ChIP coupled with
hybridization to promoter microarrays. Publicly available data for
histone PTMs for IMR90 cells was used in these analyses. Only
H3K36me3, H3K27me3 and H3K4me3 data for IMR90 cells are
shown. Except these three modiﬁcations and H3/H4 acetylation (not
shown), no other modiﬁcations were found signiﬁcantly enriched at this
set of promoters.
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were inactive in the parental cell line, we asked whether
gene expression patterns in hTERT-immortalized cells
remain stable after 50 and 100 pd in culture. We also
sought to determine whether expression of SV40 T-Ag
and constitutively active H-RASG12V in MRC-5TSR cells
had signiﬁcant role in reprogramming gene expression
proﬁles as reported for short-term studies of human cells
transformed by viral oncogenes (34,35). To address these
questions, we used microarrays to examine gene expres-
sion patterns in MRC-5hTERT and MRC-5TSR cells at 50
and 100 pd and compared these to each other and to the
parental MRC-5 cell line. Surprisingly, we found that cells
immortalized by hTERT progressively accumulate signiﬁ-
cant changes in gene expression, which were also shared
by the MRC-5TSR cells (Figure 6A). Thus, we detected
1193 transcripts that were upregulated and 571 transcripts
that were downregulated by 3-fold or more in
immortalized and transformed cells by 100 pd compared
with the parental cell line (Supplementary Table S2).
Upregulated transcripts could be divided into two
distinct groups: genes that were weakly expressed in the
MRC-5 cells, but upregulated in MRC-5hTERT and MRC-
5TSR cell lines (Group 1; upregulated), and genes that were
expressed in MRC-5hTERT and MRC-5TSR cells, but not in
the parental cell line (Group 2; activated) (Figure 6A).
Gene ontology and gene set enrichment analyses showed
that transcripts from Group 1 included proteins involved
in cytoskeletal organization and cell migration, whereas
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Figure 6. Changes in gene expression in immortalized and transformed cell lines. (A) A heat map showing immortality-associated changes in gene
expression in MRC-5hTERT and MRC-5TSR cell lines at 50 and 100 pd. Three groups of genes can be clearly distinguished. The most signiﬁcant
functions of representative up- and downregulated groups of genes identiﬁed by gene ontology and gene set enrichment analyses are indicated. (B) A
heat map representation of transformation-associated changes in gene expression in MRC-5TSR cell line in comparison with the primary MRC-5 and
immortalized MRC-5hTERT cells. The most signiﬁcantly enriched biological functions attributed to the three groups of genes are indicated.
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many of the transcripts from Group 2 encode for proteins
implicated in cancer-associated signalling pathways, regu-
lation of MAP kinase cascade, protein transport and
RNA splicing (Figure 6A). The transcripts downregulated
in MRC-5hTERT and MRC-5TSR cells (Group 3) were
enriched in regulators of cell differentiation, modulation
of transcription factor activity and proteins involved in
response to extracellular signalling. Interestingly, a
number of genes that change their expression in
immortalized cells, e.g. PI3K, MDM2, SMAD2/3 and
STAT1 (Supplementary Figure S4), are implicated in the
evasion of apoptosis and acquisition of insensitivity to
growth-inhibiting signals, which are characteristic
features of tumour cells. We validated these expression
changes by independently performed quantitative re-
verse transcription PCRs on several selected transcripts
(Supplementary Figure S6A and B).
We detected a much smaller number of up- and
downregulated transcripts (210) that could be attributed
to the constitutive expression of oncogenes, as the levels
of these mRNAs were different between MRC-5hTERT
and MRC-5TSR cells (Figure 6B and Supplementary
Table S2). Here, we also identiﬁed three distinct groups of
transcripts (labelled Groups 4, 5 and 6). The mRNAs from
Group 4 were downregulated in late passage MRC-5hTERT
cells, but these were highly expressed in MRC-5 as well as
MRC-5TSR cells and included genes involved in cell cycle
regulation such as Securin, CDC25 phosphatase and the
kinase Aurora B. The transcripts from Group 5 were
enriched for regulators of transport and cell–cell signalling
and were expressed neither in MRC-5 nor in MRC-5hTERT
cells, but were progressively upregulated exclusively in the
transformed MRC-5TSR cell line (Figure 6B). Finally,
Group 6 included transcripts that were upregulated in the
immortalized MRC-5hTERT cells, but expressed in the
MRC-5TSR cell at levels comparable with the parental cell
line. This group was enriched in regulators of cell growth,
tissue morphogenesis and nucleosome assembly. As
expected, many of the proteins with altered levels of expres-
sion in MRC-5TSR cells belong to cancer-associated
signalling pathways and have roles in promoting cellu-
lar proliferation, angiogenesis and cell survival
(Supplementary Figure S5). Although some of these com-
ponents are upregulated already inMRC-5hTERT cells, their
levels of expression are further enhanced upon introduction
of oncogenes. Independently performed quantitative
reverse transcription PCRs on a subset of transcripts were
in agreement with the microarray data (Supplemental
Figure S6C and D).
Taken together, these analyses demonstrate that sus-
tained expression of hTERT leads to signiﬁcant and
complex large-scale reprogramming of the transcriptional
output of the genome, which is likely to reﬂect adaptation
to highly proliferative state. On the other hand, expression
of SV40 T-Ag and oncogenic H-RASV12G in hTERT-
immortalized cells induces fewer sustainable changes in
gene expression, but these might be essential for
tumorigenisity and acquisition anchorage-independent
growth.
DISCUSSION
Aberrant DNA methylation at gene promoters has been
reported for many tumours and typically is accompanied
by lack of transcription from the associated gene.
Although there are many speciﬁc examples of silencing
of tumour suppressor genes by promoter DNA methyla-
tion, recent high-throughput analyses in breast, colorectal
and other types of cancer have suggested that the vast
majority of gene promoters methylated in tumours repre-
sent developmentally regulated loci, which are already
repressed in pre-cancerous tissues (36,37). These observa-
tions highlight the coexistence of ‘driver’ and ‘passenger’
de novomethylation events that occur in tumours implying
that most changes in DNA methylation at gene promoters
are unlikely to contribute to cancer formation (15,38,39).
Nevertheless, several important questions arise from
these studies. How are the aberrant patterns of DNA
methylation brought into existence? What are the
dynamics of de novo DNA methylation and the molecular
determinants of this process? Are epigenetic alterations
linked intrinsically to genetic determinants of tumour
formation?
To address some of these questions, we used a model
system, which allows deﬁned genetic components to be
sequentially introduced into primary human cells with
normally ﬁnite life in culture. The contribution of these
genetic components to changes in growth characteristics
of modiﬁed cells, gene expression patterns and promoter
DNA methylation could then be examined by high-
throughput assays. Thus, the expression of the catalytic
subunit of telomerase enzyme (hTERT) in MRC-5 foetal
lung ﬁbroblasts generated an immortal cell line with
life span extended for >200 cell generations, whereas
further expression of collaborating oncogenes, SV40
T-Ag and H-RASV12G, in hTERT-immortalized cells
produced an isogenic transformed cell line characterized
by acquisition of anchorage-independent growth. Our
detailed investigation of promoter DNA methylation in
these two isogenic cell lines identiﬁed loci that are prone
to time-dependent de novoDNA methylation and led us to
conclude that the changes in DNA methylation at pro-
moters do not require expression of oncogenes. Near iden-
tical changes in DNA methylation at gene promoters took
place in the immortalized (MRC-5hTERT) and transformed
(MRC-5TSR) cell lines with stable diploid karyotype. This
is somewhat surprising given that constitutively active
K-RAS and H-RAS have been implicated in DNA methy-
lation-mediated silencing of speciﬁc genes (40,41). In
contrast to these ﬁndings, our data ﬁrmly suggest that
cellular immortality conferred by hTERT expression is
sufﬁcient to promote de novo DNA methylation at gene
promoters. Whether the immortal and transformed cells
display differences in DNA methylation elsewhere in the
genome is yet to be determined.
In agreement with recent studies (42), the vast majority
of de novo DNA methylation events in MRC-5hTERT and
MRC-5TSR cell lines occurred at promoters of genes that
were already silenced in the parental cell line. Some of
these represent loci carrying repressive H3K27me3 and
H3K36me3 histone modiﬁcations. However, it seems
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unlikely that histone modiﬁcations determine whether or
not a promoter will become methylated in immortalized
cells. About 40% of the loci hypermethylated in MRC-
5hTERT and MRC-5TSR cells were devoid of H3K27me3
and H3K36me3 in the parental cell line and had no other
detectable known modiﬁcations in the closely related
IMR90 ﬁbroblasts. Taken together, these data suggest
that lack of promoter activity and, potentially, stably
bound transcription factors, which could protect such
loci against DNA methylation machinery (43,44), may
result in gradual acquisition of DNA methylation over
time. Our data also indicate that promoters of actively
transcribed genes, marked by H3 acetylation and
H3K4me3, tend to be more stably protected. Few active
promoters became methylated in the immortal cells, and
in all cases this occurred at late passage. In contrast to
silenced genes, methylation of active promoters could rep-
resent rare driver methylation events, which promote cell
proliferation and survival. It is plausible that stochastic
DNA methylation events take place in immortalized
cells, and these patterns are under constant surveillance
and selection. Therefore, only those methylation events
that occur either at weakly protected silenced promoters
or genes, inactivation of which favours long-term survival,
will be tolerated and stably propagated in the immortal
cell populations. As immortality, and in many cases the
expression of hTERT (45), is a hallmark of all tumours,
this may explain why aberrant DNA methylation is such a
prevalent feature in a variety of cancer cell types.
Another essential feature of hTERT-immortalized cells
is time-dependent acquisition of large-scale changes in gene
expression (42,46). Given the stable diploid karyotype
of MRC-5hTERT cells, these expression patterns must be
epigenetic by nature, as they cannot be explained by aneu-
ploidy or alterations in DNA sequence. In contrast to de
novoDNA methylation events, the changes in gene expres-
sion observed inMRC-5hTERT cells are likely to result from
selective pressure to enhance traits that favour long-term
survival and stable proliferation in culture. As the evasion
of apoptosis, effective repair of DNA damage and robust
progression through the cell cycle are essential properties
of tumour cells, it is probably not surprising that proteins
with known function in cancer-associated signalling
pathways show altered expression in the immortal cells.
Although subsequent introduction of SV40 T-Ag and con-
stitutively active H-RAS into hTERT-immortalized cells
results in fewer high-amplitude changes in gene expression,
our data indicate that the presence of cooperating onco-
genes promotes subtle alterations in many signalling
pathways, confers insensitivity to growth signals and
acquisition of anchorage-independent growth. Taken
together, these observations imply that telomerase-
induced immortality is sufﬁcient for large-scale repro-
gramming of DNA methylation at gene promoters and
expression patterns in diploid human cells to a state that
resembles pre-cancerous lesions. Such reprogramming
reﬂects the intrinsic plasticity of immortal cell genome
which, in combination with oncogene-dependent modula-
tion of responses to stress and growth signals, may favour
adaptation to a variety of cellular and tissue microenviron-
ments and ultimately support tumour growth.
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